Cytoplasmic expression of estrogen receptor beta (ERβ) predicts poor clinical outcome in advanced serous ovarian cancer

Ilaria De Stefano; Gian Franco Zannoni; Mg Prisco; Anna Fagotti; L Tortorella; Giuseppe Vizzielli; L Mencaglia; Giovanni Scambia; D. Gallo

doi:10.1016/j.ygyno.2011.05.025

Cytoplasmic expression of estrogen receptor beta (ERβ) predicts poor clinical outcome in advanced serous ovarian cancer

Ilaria De Stefano, Gian Franco Zannoni, Mg Prisco, Anna Fagotti, L Tortorella, Giuseppe Vizzielli, L Mencaglia, Giovanni Scambia, D. Gallo

Risultato della ricerca: Contributo in rivista › Articolo in rivista

Abstract

In this study we investigated the prognostic value of estrogen receptor α (ERα), ERβ and progesterone receptor (PR) expression in 58 untreated advanced serous ovarian cancer patients. The study also included 12 macroscopically and histopathologically normal ovaries.

Lingua originale	English
pagine (da-a)	573-579
Numero di pagine	7
Rivista	Gynecologic Oncology
Volume	122
Numero di pubblicazione	3
DOI	https://doi.org/10.1016/j.ygyno.2011.05.025
Stato di pubblicazione	Pubblicato - 2011

Keywords

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Carboplatin
Cell Nucleus
Cisplatin
Cohort Studies
Cystadenocarcinoma
Cytoplasm
Disease-Free Survival
Estrogen Receptor alpha
Estrogen Receptor beta
Female
Humans
Immunohistochemistry
Middle Aged
Ovarian Neoplasms
Paclitaxel
Progesterone
Receptors
Serous

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1016/j.ygyno.2011.05.025

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{5056278953904bbcb2ae6723dc312925,

title = "Cytoplasmic expression of estrogen receptor beta (ERβ) predicts poor clinical outcome in advanced serous ovarian cancer",

abstract = "In this study we investigated the prognostic value of estrogen receptor α (ERα), ERβ and progesterone receptor (PR) expression in 58 untreated advanced serous ovarian cancer patients. The study also included 12 macroscopically and histopathologically normal ovaries.",

keywords = "Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Cell Nucleus, Cisplatin, Cohort Studies, Cystadenocarcinoma, Cytoplasm, Disease-Free Survival, Estrogen Receptor alpha, Estrogen Receptor beta, Female, Humans, Immunohistochemistry, Middle Aged, Ovarian Neoplasms, Paclitaxel, Progesterone, Receptors, Serous, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Cell Nucleus, Cisplatin, Cohort Studies, Cystadenocarcinoma, Cytoplasm, Disease-Free Survival, Estrogen Receptor alpha, Estrogen Receptor beta, Female, Humans, Immunohistochemistry, Middle Aged, Ovarian Neoplasms, Paclitaxel, Progesterone, Receptors, Serous",

author = "{De Stefano}, Ilaria and Zannoni, {Gian Franco} and Mg Prisco and Anna Fagotti and L Tortorella and Giuseppe Vizzielli and L Mencaglia and Giovanni Scambia and D. Gallo",

year = "2011",

doi = "10.1016/j.ygyno.2011.05.025",

language = "English",

volume = "122",

pages = "573--579",

journal = "Gynecologic Oncology",

issn = "1095-6859",

publisher = "Academic Press Inc.",

number = "3",

}

TY - JOUR

T1 - Cytoplasmic expression of estrogen receptor beta (ERβ) predicts poor clinical outcome in advanced serous ovarian cancer

AU - De Stefano, Ilaria

AU - Zannoni, Gian Franco

AU - Prisco, Mg

AU - Fagotti, Anna

AU - Tortorella, L

AU - Vizzielli, Giuseppe

AU - Mencaglia, L

AU - Scambia, Giovanni

AU - Gallo, D.

PY - 2011

Y1 - 2011

N2 - In this study we investigated the prognostic value of estrogen receptor α (ERα), ERβ and progesterone receptor (PR) expression in 58 untreated advanced serous ovarian cancer patients. The study also included 12 macroscopically and histopathologically normal ovaries.

AB - In this study we investigated the prognostic value of estrogen receptor α (ERα), ERβ and progesterone receptor (PR) expression in 58 untreated advanced serous ovarian cancer patients. The study also included 12 macroscopically and histopathologically normal ovaries.

KW - Adult

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Carboplatin

KW - Cell Nucleus

KW - Cisplatin

KW - Cohort Studies

KW - Cystadenocarcinoma

KW - Cytoplasm

KW - Disease-Free Survival

KW - Estrogen Receptor alpha

KW - Estrogen Receptor beta

KW - Female

KW - Humans

KW - Immunohistochemistry

KW - Middle Aged

KW - Ovarian Neoplasms

KW - Paclitaxel

KW - Progesterone

KW - Receptors

KW - Serous

KW - Adult

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Carboplatin

KW - Cell Nucleus

KW - Cisplatin

KW - Cohort Studies

KW - Cystadenocarcinoma

KW - Cytoplasm

KW - Disease-Free Survival

KW - Estrogen Receptor alpha

KW - Estrogen Receptor beta

KW - Female

KW - Humans

KW - Immunohistochemistry

KW - Middle Aged

KW - Ovarian Neoplasms

KW - Paclitaxel

KW - Progesterone

KW - Receptors

KW - Serous

UR - https://publicatt.unicatt.it/handle/10807/27827

U2 - 10.1016/j.ygyno.2011.05.025

DO - 10.1016/j.ygyno.2011.05.025

M3 - Article

SN - 1095-6859

VL - 122

SP - 573

EP - 579

JO - Gynecologic Oncology

JF - Gynecologic Oncology

IS - 3

ER -

Cytoplasmic expression of estrogen receptor beta (ERβ) predicts poor clinical outcome in advanced serous ovarian cancer

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo